Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL
Oncology and Therapy · 2026-06 · 14 (2) · 693-705
DOI: 10.1007/s40487-026-00430-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Therapy, online erschienen am 01.04.2026. Verfasst von Brian Poligone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rochester Skin Lymphoma Medical Group, PLLC, Fairport, NY, 14450, USA. bpoligone@roclymphoma.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Soligenix, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rochester Skin Lymphoma Medical Group, PLLC, Fairport, NY, 14450, USA. bpoligone@roclymphoma.com.
- Soligenix Inc., Princeton, NJ, USA.
- Rochester Skin Lymphoma Medical Group, PLLC, Fairport, NY, 14450, USA.
ORCID-Profile: Christopher J Schaber
Förderung
- Soligenix, Inc.
Zitieren
APA
Poligone, B., Pullion, C., Rumage, A., Straube, R., Donini, O., Schaber, C. J., & Gilmore, E. S. (2026). Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL. Oncology and Therapy, 14(2), 693-705. https://doi.org/10.1007/s40487-026-00430-1
Vancouver
Poligone B, Pullion C, Rumage A, Straube R, Donini O, Schaber CJ, et al. Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL. Oncology and Therapy. 2026;14(2):693-705. doi:10.1007/s40487-026-00430-1
BibTeX
@article{Poligone2026,
author = {Poligone, Brian and Pullion, Christopher and Rumage, Adam and Straube, Richard and Donini, Oreola and Schaber, Christopher J and Gilmore, Elaine S},
title = {Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL},
journal = {Oncology and Therapy},
year = {2026},
volume = {14},
number = {2},
pages = {693--705},
doi = {10.1007/s40487-026-00430-1}
}
EUVIMED